Peters, D., Abbott, D., Zhang, J., Fang, J., Pan, Z., Schowinsky, J., Gutman, J., Kent, A., Angelos, M., McMahon, C., Amaya, M., Schwartz, M., Xie, W., Galeotti, J., Buss, J., Eisfeld, A., Lachowiez, C., Zeidner, J., Pollyea, D. (2025). Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML. Blood. https://doi.org/10.1182/blood-2025-3377